Transition to a life sciences AI and DX business under the medium-term strategy "Stage 4"

A theme focused on 2158's portfolio reorganization under its medium-term strategy, "Stage 4," establishing business models in AI drug discovery and economic security with life sciences AI as the core business, while incorporating DX for manufacturers through the acquisition of アルネッツ as a subsidiary.